|Articles|October 8, 2021
- Pharmaceutical Executive-10-01-2021
- Volume 41
- Issue 10
Pharmaceutical Executive, October 2021 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive October 2021 issue in an interactive PDF format.
Advertisement
Articles in this issue
about 4 years ago
Addressing Systemic Racism in Biopharmaabout 4 years ago
Understanding the HCP: Patient-Level Data Proves Valuableabout 4 years ago
Industry Game Changer: RWE Impacts on Drug Developmentabout 4 years ago
Opposites Attractabout 4 years ago
Defining the Chief Data Officerabout 4 years ago
Leading Through Transitionabout 4 years ago
Biotech Stocks Continue With Underperformanceabout 4 years ago
Could Time Be the Next New Element in Pharma Revenue?about 4 years ago
Sharing the Science: Pharma’s Content Evolutionabout 4 years ago
Data Science Calls for Shift in Executive Leadership MethodsNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Mark Cuban Pushes for Generic Drug Fee Waivers, as Cost Plus Drugs Eyes US Manufacturing Expansion
2
Pharmaceutical Executive Daily: FDA Names Tracy Beth Høeg as Acting Director of CDER
3
FDA Appoints Tracy Beth Høeg as Acting Director of CDER
4
FDA Approves Breyanzi for Adults with Relapsed or Refractory Marginal Zone Lymphoma
5
